GBR - New Concept Energy, Inc.
TERN
Terns Pharmaceuticals, Inc.
49.61
2 x 36.13
2 x 61.97
bid
ask
+
1.17
2.42%
2 @ 07:03 AM
50.64 +1.03 (2.08%)
Ytd 22.80%
1y 1380.90%
47.63
day range
50.81
1.86
52 week range
50.89
Open 49.71 Prev Close 48.44 Low 47.63 High 50.81 Mkt Cap 5.40B
Vol 3.58M Avg Vol 2.20M EPS -1.02 P/E N/A Forward P/E -39.06
Beta -0.29 Short Ratio 8.20 Inst. Own 118.97% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 03-25 50-d Avg 39.91 200-d Avg 20.72 1yr Est 58.11
Earning
Date For Estimate Reported Surprise surprise %
2026-03-19 2025-12 0 N/A N/A N/A
2025-11-10 2025-09 0 N/A 0.03 10.00%
2025-08-05 2025-06 0 N/A 0.02 7.14%
2025-08-05 2025-06 0 N/A N/A N/A
2025-05-08 2025-03 0 N/A 0.03 10.34%
2025-05-08 2025-03 0 N/A N/A N/A
Upgrade / Downgrade
Date Firm Action From To
2025-12-11 Citizens Upgrade Market Outperform Market Outperform
2025-12-09 Truist Securities Upgrade Buy Buy
2025-12-09 Oppenheimer Upgrade Outperform Outperform
2025-12-09 BMO Capital Upgrade Outperform Outperform
2025-12-09 Barclays Upgrade Overweight Overweight
2025-12-09 Mizuho Upgrade Outperform Outperform
Profile
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Insider Holder
Date Name Relation Quantity Description
2026-03-15 BURROUGHS AMY LOUISE Chief Executive Officer 297.30K Sale
2026-01-13 GENGOS ANDREW Chief Financial Officer 101.79K Stock Award(Grant)
2024-07-15 GORDON CARL L Director and Beneficial Owner of more than 10% of a Class of Security 0.00 Sale
2026-01-13 KURIAKOSE EMIL T. Officer 106.62K Stock Award(Grant)
2024-09-11 LU HONGBO B Director 0.00 Purchase
2024-07-15 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security 0.00 Sale
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Blackrock Inc. 8.19M 406.52M 9.10%
2025-12-30 Morgan Stanley 7.95M 394.18M 8.82%
2025-12-30 Adage Capital Partners GP L.L.C. 5.55M 275.34M 6.16%
2025-12-30 Vanguard Group Inc 5.52M 274.04M 6.13%
2025-12-30 Vivo Capital, LLC 5.35M 265.26M 5.94%
2025-12-30 Vestal Point Capital, LP 4.50M 223.25M 5.00%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 3.18M 158.01M 3.54%
2026-01-30 iShares Trust-iShares Russell 2000 ETF 2.05M 101.58M 2.27%
2026-01-30 Fidelity Select Portfolios-Select Biotechnology Portfolio 1.11M 54.88M 1.23%
2025-12-30 SmallCap World Fund Inc 1.06M 52.59M 1.18%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund 927.85K 46.03M 1.03%
2025-12-30 Fidelity Salem Street Trust-Fidelity Small Cap Index Fund 840.90K 41.72M 0.93%
Split
Split Date
2 : 1 2000-05-05